23 results about "Substance use" patented technology

A device for inhaling powder-type substances includes a plurality of substance containers that can be moved successively into an emptying position, wherein the substance containers—which are not connected to one another—are accommodated in direct contact with one another in a guide unit attached to the device and can be moved by contact pressure propagating among the substance containers. The guide unit has a drive wheel with accommodating forms separated by drive teeth. The substance container in the emptying position is located in an accommodating form of the drive wheel. A substance container for a device for inhaling powder-type substances has two sub-regions, each separately having an amount of the substance, and both sub-regions have an openable, pierceable cover. A method for filling a device for inhaling powder-type substances uses a plurality of substance containers that can be moved successively into an emptying position.

The present invention discloses a system and method for managing treatment plans and clinical documentation for substance use disorder (SUD) treatment. The system includes user devices associated with clients, clinicians, organization representatives, and supervisors. The system connects to a database storing client data, clinician data, assessment scores, and clinical documentation such as SOAP notes and progress notes. A computing device with artificial intelligence (AI) modules executes various program modules. A data collection module guides clinicians through predefined questions to gather information for generating SOAP and clinical progress notes. A secondary data collection module collects clarification from the counselor without requiring client input. A review module allows counselors to review, edit, approve, and submit documentation. A treatment plan generation module creates or updates plans based on collected data and prior scores. The system improves documentation efficiency, quality, and compliance, while supporting accurate and personalized treatment planning.

The present invention discloses a system for managing treatment of behavioral health conditions including substance use disorder (SUD). The system comprises a computing device in communication with a database and user devices via a network. The computing device provides a questionnaire comprising a plurality of categories. Each category comprises a set of questions to assess progress of the client. The computing device enables a clinician to input a score for each question based on analyzing response of client to each question. The computing device is configured to apply predefined scoring guidelines for the input score and generate the score data including the category score data for each category and the recovery score data for the questionnaire. The computing device enables the clinician to continuously evaluate and track the progress of the client, and provide a treatment plan based on current score data and progress data of the client.

The present invention relates to compounds of general formula (I), wherein the groups R1, R2 and n are defined as in claim 1, which are ghrelin O-acyl transferase (GOAT) inhibitors for use in the treatment of substance use disorder (SUD,) in particular for use in the treatment of opioid use disorder (OUD) or stimulant use disorder (StimUD), in patients with high impulsivity.

This invention relates to the use of (i) a 5-HT2A agonist (including 5-HT2A agonists that bind to a BDNF receptor, e.g., a 5-HT2A agonist that binds to the TrkB receptor or p75NTR), (ii) a therapeutic agent that promotes neuroplasticity by stimulation of the 5-HT2A receptor, (iii) a therapeutic agent that releases BDNF by stimulation of the 5-HT2A receptor (including those therapeutic agents that stimulate the 5-HT2A receptor and bind to a TrkB receptor or p75NTR), (iv) an AMPA positive allosteric modulator, (v) a therapeutic agent that promotes neuroplasticity by stimulation of the AMPA receptor, (vi) a therapeutic agent that releases BDNF by stimulation of the AMPA receptor, or (vii) an NMDA receptor positive allosteric modulator (such as a stinel compound) in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who, for instance, have objectively determined cognitive impairment or poor cognition (such as objectively determined impaired learning and / or memory) and / or certain EEG characteristics.

Methods and compositions are disclosed for rapidly relieving symptoms in subjects with depressive, stressor and substance abuse conditions, e.g., major depression, treatment-resistant depression, post-partum depression, bipolar depression, post-traumatic stress disorder, substance use disorders, negative and cognitive symptoms of schizophrenia, as well as for slowing progression of mild cognitive impairment and dementia, using an intermittent dosing regimen of memantine or amantadine or a structural analogue or pharmaceutically acceptable salt of memantine or amantadine (optionally no more frequently than every 2 days) at a dose sufficient to activate Set A brain structures, in combination with a second drug at a dose which activates Set B brain structures but which does not appreciably evoke brain activity linked to hallucinogenic and other psychotomimetic perceptions. In some instances the second drug is either 1) a low dose psilocybin or low dose of other psychedelic and stimulant molecules capable of activating Set B of brain structures which is administered at a dose low enough such that it does not appreciably evoke brain activity linked to hallucinogenic and other psychotomimetic perceptions, or is 2) mianserin (S isomer, R isomer, or a racemate comprising both isomers or structural analog or pharmaceutically acceptable salt thereof) or another standard of care antidepressant capable of activating Set B brain structures, or 3) lumateperone or another antipsychotic capable of activating Set B brain structures.

A combination therapy for use in treatment of substance abuse disorders, including alcohol use disorder (AUD) and opioid use disorder (OUD), includes both mitragynine (MG) and naltrexone (NTX). NTX is understood to be a mu opioid antagonist that is expected to block MG's analgesic effects. However, combining MG and NTX therefore results in a unique, unexpected, and beneficial treatment that decreases alcohol self-administration to a greater extent than either alone.

This invention relates to the use of mGluR5 positive allosteric modulators in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, post-traumatic stress disorder, substance use disorder, depression-related aspects of schizophrenia (e.g. negative symptoms and cognitive impairment associated with schizophrenia), obsessive compulsive disorder, an eating disorder, autism spectrum disorder, chemotherapy-related cognitive dysfunction, Parkinson's disease, multiple sclerosis, clinical high risk for psychosis, and attenuated psychosis syndrome in select patients who, for instance, have objectively determined cognitive impairment or poor cognition (such as objectively determined impaired learning and / or memory) and / or certain EEG characteristics.

This application provides a gene construct and its uses, which is used to inhibit neuronal overexcitation caused by the overuse or abuse of addictive substances. The gene construct comprises a neuronal inhibitory protein-coding gene and a promoter operatively linked to the neuronal inhibitory protein-coding gene. The gene construct exhibits significant advantages in precise targeting, closed-loop regulation, preservation of natural reward responses, reduced side effects and improved safety, and potential long-term efficacy and sustainability. This strategy provides new ideas and methods for the treatment of substance use disorders and is expected to become a significant breakthrough in the field of substance use disorders in the future.

Provided herein are non-naturally occurring melanocortin analogs that selectively bind at least a portion of a melanocortin receptor The melanocortin receptor may be a melanocortin 3 receptor (MC3R) or a melanocortin 4 receptor (MC4R). The non-naturally occurring melanocortin analogs may have a dissociation constant (Kd) value for a melanocortin receptor or one or more amino acids thereof that is less than that of a conventional melanocortin analog.

Disclosed are compounds having the structure:whereinZ1 is NR4, O, or S;Z2 is CR7 or N;n is 1 to 5;R1 is —H, halogen, —O-alkyl, or together with R2 forms —O—CH2—O—;R2 is —H, —OH, —O-alkyl, —O-alkyl-aryl, —S-alkyl, —S-alkyl-aryl, or together with R1 or R3 forms —O—CH2—O—;R3 is —H, —O-alkyl or together with R2 forms —O—CH2—O—;R4 is H or alkyl;R5 and R6 are each independently H, alkyl, alkenyl, alkynyl or NR5R6 together form a substituted or unsubstituted heterocycle, wherein the heterocycle may be monocyclic or bicyclic,R7 is H or alkyl;wherein R1 is F, when R2 is —O-(n-propyl) or when at least one of R5 or R6 is H, andwherein the compound is other than a compound whereZ1 is NR4 and R1, R2, R3, and R8 are H;n is 2, R1 is halogen, R2 is —OCH3, R3 is —H, R4 is —H, and R5 and R6 are both methyl;n is 2, R1 is —F, R2 is —OCH3, R3 is —H, R4 is —H, and NR5R6 together are —N-pyrrolidine;n is 2, R1 and R2 together forms —O—CH2—O—, R3 is —H, R4 is —H, and R5 and R6 are both methyl; andn is 2, R1 and R2 together forms —O—CH2—O—, R3 is —H,R4 is —H; and R5 and R6 are both isopropyl,or a pharmaceutically acceptable salt thereof.Also disclosed are processes for synthesizing the compounds, and methods for activating or selectively activating the 5HT1A receptor, or of simultaneously activating the 5HT1A and 5HT2A receptors, and of treating a subject afflicted with a neurological disease, psychiatric disorder, or substance use disorder, using the compounds.

The present invention relates to the treatment of psychiatric or neurological disorders in patients in need of pleasant sensation (lack of pleasure or pursuit of incentive activities) by administering idarsone or a pharmaceutically acceptable salt thereof as a monotherapy or in combination with an antipsychotic agent. Examples of such psychiatric or neurological disorders include major depressive disorder, bipolar depression (such as bipolar type I or bipolar type II disorder), post-traumatic stress disorder, substance use disorder, pleasant sensation loss related aspects of schizophrenia (e.g., negative symptoms), and split affective disorder (e.g., with emotional and / or negative symptoms).

Disclosed herein are compounds, compositions and methods for the treatment of neurological, psychiatric disorders which are characterized by a fundamental disruption of social behaviour, and substance use disorders. In particular, disclosed herein are compounds of Formula (I), or salts or prodrugs thereof. Methods of treating or preventing neurological, psychiatric disorders and substance use disorders, using compounds of Formula (I), or salts and prodrugs are also disclosed.

The present disclosure generally relates to methods of treating various diseases, disorders, and conditions, such as depressive disorders (e.g., major depressive disorder (MDD)), substance use disorders, anxiety disorders, eating disorders, pain, and headache disorders, via administration of deuterated psilocin and its pharmaceutically acceptable salts, polymorphs, or solvates.

Provided herein are pharmaceutical compositions of non-naturally occurring melanocortin agonist analogs formulated for oral administration. The non-naturally occurring melanocortin agonist analog comprises a sequence of Formula (I): Ac-Nle-c[Glu-Pro-p(F)dPhe-Arg-Trp-Orn]-dVal-dPro-NH2 (SEQ ID NO: 2), wherein c represents cyclization via a lactam bond.

The present invention relates to compounds of general formula I,wherein the groups R1, R2 and n are defined herein, which are ghrelin O-acyl transferase (GOAT) inhibitors. The invention also relates to the use of compounds of formula (I) for treatment of substance use disorder (SUD,) in particular for use in the treatment of opioid use disorder (OUD) or stimulant use disorder (StimUD), in patients with high impulsivity.

The invention belongs to the cross technical field of biological medicine and neuropsychiatric medicine, and particularly relates to application of an SAA1 protein inhibitor in preparation of a medicine for treating methylamphetamine addiction withdrawal syndrome. The invention reveals that the mesenteric white adipose tissue plays a key role in anxiety, depression and other negative emotions induced by withdrawal of methylamphetamine by secreting SAA1 protein for the first time, and further obviously increases the drug foraging behavior and relapse risk. By inhibiting or reducing SAA1 protein expression or activity from mesenteric white fat, negative emotion related to withdrawal can be effectively relieved, so that psychological desire and relapse rate are reduced. The invention provides an inhibitor taking SAA1 protein as a target spot, an antibody, a gene silencing tool or application thereof. The inhibitor, the antibody and the gene silencing tool are used for preparing drugs or preparations for treating methylamphetamine addiction withdrawal syndrome and preventing relapse. The target and the treatment method provide a brand new way and strategy for material use disorder, especially clinical intervention of methamphetamine dependence.

The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence / abuse / addiction and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.

Systems and methods for managing data structures for remote monitoring and validation of user devices are described herein. A computing system can maintain a data structure including an activity field and a validation field, and determine that activity data generated in response to a user performing an activity via an application satisfies an activity condition. The computing system can update the data structure to include an activity value, and receive validation data. The computing system can update the data structure to include a validation value, and perform an operation to update a profile using a token based on the activity value and the validation value. The computing system can improve the efficacy of a medication regimen for a user condition.

Described herein are novel compounds for use in treating substance addiction and withdrawal induced anxiety and depression, and methods of treating addictions and substance use disorders including alcohol abuse, opioid abuse, and nicotine abuse using compositions comprising MC-100093, wherein the compositions may further comprise ceftriaxone and / or additional therapeutic agents.

The invention features methods for using 5-methoxy-N,N-dimethyltryptamine (5'MeO-DMT) in the treatment of substance use disorders (SUD), including specifically alcohol use disorder (AUD). Provided are specific therapeutically effective doses of 5-MeO-DMT which are well tolerated by patients and sufficient to induce a clinical response in the patient.

Described herein are i) sequestering agents and ii) central nervous system (CNS) active agents for the treatment of intoxication due to toxic agents such as drugs of abuse, and associated symptoms. Also disclosed herein, are a cucurbituril and naloxone for use in the treatment of opioid overdoses through sequestering and excretion of the bound molecule of interest through the urine. Also provided herein, are kits and methods of treatment of the disclosure.

The present disclosure relates to methods for treating subjects having a substance use disorder (SUD) with 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 negative allosteric modulators. Specifically, in some embodiments, this disclosure relates to methods of treating a subject having SUD who is at risk of relapse to alcohol use. In some embodiments, this disclosure relates to methods of promoting remission in a subject having SUD. In some embodiments, the SUD is alcohol use disorder (AUD), opioid use disorder (OUD), or a stimulant use disorder such as cocaine use disorder (CUD).